Generated by AI
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases by targeting the biology of human aging. BioAge Labs, Inc. advances a pipeline of product candidates designed to address conditions such as obesity and other age-associated disorders, using human data and molecular insights to identify drug targets linked to healthy aging. Its current programs include orally available small-molecule candidates and inhibitors aimed at cardiometabolic and neuroinflammatory disease pathways. The company’s work spans therapeutic development in obesity, cardiovascular risk, retinal disorders, and other metabolic indications, positioning it as a research-driven participant in the biotechnology sector. BioAge Labs, Inc. operates with a translational approach that connects aging biology to drug discovery, supporting the development of medicines intended to treat diseases with common biological mechanisms.
The latest articles about BIOA.
EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ('BioAge', 'the Company'), a clinical-stage biopharmaceut...
First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027 QUELL-CV, a Phase 2 dose-ranging trial of BGE-102 in adults with obesity and elevated baseline inflammation, completed enrollment; topline data anticipated in the fourth quarter of 2026 APJ agonist program, an exercise-mimetic approach to obesity, on track for IND submission by year-end 2026 EMERYVILLE,
BioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Detailed price information for Bioage Labs Inc (BIOA-Q) from The Globe and Mail including charting and trades.
Summary of Oct 20's posts. Generated by AI.
No summary yet.
Summary of Jan 13's posts. Generated by AI.
Summary of Jul 31's posts. Generated by AI.
No summary yet.
Summary of Oct 20's posts. Generated by AI.
Investors talking about BIOA also mention these. Each card shows that asset’s own numbers for the past 24 hours.